Nesvacumab

From Wikipedia, the free encyclopedia
Nesvacumab ?
Monoclonal antibody
Source Human
Target angiopoietin 2
Clinical data
Legal status ?
Identifiers
CAS number 1296818-77-3
ATC code None
Chemical data
Formula C6440H9966N1722O2008S38 
Mol. mass 144.9 kDa

Nesvacumab is a monoclonal antibody designed for the treatment of cancer.[1]

This drug was developed by Regeneron Pharmaceuticals.

References

  1. ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Nesvacumab, American Medical Association.
Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems
Bone ("-os-", "-s(o)-")
Human ("-osu-")
Humanized ("-sozu-")
Musculoskeletal ("-mul-")
Human ("-mulu-")
Circulatory ("-c(i[r])-")
Human ("-ciru-")
Mouse ("-ciro-")
Chimeric ("-cixi-")
Humanized ("-cizu-")
Neurologic ("-ne(u)(r)-")
Human ("-neru-")
Humanized ("-nezu-"/"-neuzu-")
Angiogenesis inhibitor ("-anibi-")
Humanized ("-anibizu-")
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.